MultNAT® INH/FLQ Assay
Product Overview
MultNAT® INH/FLQ Assay is intended for the in vitro qualitative detection of mutations in isoniazid (INH) resistance-associated genes (inhA, ahpC, katG) and fluoroquinolones (FLQ) resistance-associated genes (gyrA and gyrB) in human sputum samples that have tested positive for Mycobacterium tuberculosis. This product is not capable of identifying the specific mutation types. And is intended for use as an aid in the diagnosis of isoniazid- and fluoroquinolone-resistant tuberculosis.
- Precise result less than 150 minutes.
- Easy to use and control the hands-on time within 2 mins
- Point-of-care Nucleic Acid Testing applicable across diverse medical settings.
Ongoing Challanges
- According to the WHO report, an estimated 10.8 million people developed TB worldwide in 2023, of whom over 90% were from 30 high TB burden countries
- DR-TB is a major public health threat. Isoniazid (INH) is one of the primary drugs used to control TB, and fluoroquinolones (FLQ) are the most effective second-line anti-TB drugs
- Affected by the limitation of diagnostics, sputum smear microscopy misses ~50% of cases; culture takes 2–8 weeks. Molecular tests are costly and lack sensitivity for paucibacillary TB (children/HIV+ patients)
Clinical Value
Higher detection rate: Molecular high sensitivity/specificity boosts positivity in adult, pediatric, smear-negative PTB
Lower costs: Resistance testing enables accurate treatment reduces complications, mortality, overall expenditure, and insurance burden
Better testing capacity: Suitable for grassroots & frontline screening, improves primary TB control and facility-level detection/resistance testing
